Chantel Hillestad, RN, MSN, DCNP, FNP-C: Treating Patients with Vitiligo on the Hands

October 14, 2025

Chantel Hillestad discusses the unique challenges involved in treating Vitiligo affecting the hands, an area that is often more resistant to repigmentation due to lower follicular density. Her presentation also explores how UV exposure can increase the visibility and presentation of vitiligo lesions by enhancing contrast between affected and unaffected skin.

Topics Covered

Treatment options for vitiligo involving the hands
Why acral areas can be more difficult to repigment
The impact of UV exposure on vitiligo presentation
Counseling patients on sun protection and long-term management

Explore Related Resources

MORE EXPERT PERSPECTIVES IN VITILIGO

Tristan Hasbargen, PA-C: Setting Expectations for a Long-Term Approach to Repigmentation

Tristan Hasbargen, PA-C, of Dermatology Associates of Tallahassee, discusses the treatment of Vitiligo, with a focus on helping patients develop realistic expectations for the repigmentation

David Rosmarin, MD: Efficacy of Ruxolitinib Cream in Progressive and Stable Vitiligo

David Rosmarin, MD, the chair of the Department of Dermatology at Indiana University in Indianapolis, discusses results from a pooled subgroup analysis of the 104-week

Seemal Desai, MD, FAAD: Providing Effective Treatment for Patients with Facial Vitiligo

Dr. Desai discusses treatment strategies for patients with Vitiligo, focusing specifically on the use of Ruxolitinib> cream 1.5% for depigmented areas affecting the face and

Chantel Hillestad, RN, MSN, DCNP, FNP-C: Restoring Pigmentation in Patients with Vitiligo

Chantel Hillestad, RN, MSN, DCNP, FNP-C, shares clinical experience using ruxolitinib to restore pigmentation in vitiligo patients across all age groups. Topics Covered: Ruxolitinib for

Seemal Desai, MD, FAAD: Assessing Efficacy of Ruxolitinib in Characteristic Subgroups for Patients with Vitiligo

Dr. Desai reviews findings from a post-hoc analysis of the TRuE-V1 and TRuE-V2 clinical trials, focusing on the efficacy and durability of treatment with Ruxolitinib>

Jennifer Silva, APRN-DNP: Safety Considerations for Treating Patients with Vitiligo

Jennifer Silva discusses important safety considerations when treating patients with Vitiligo using JAK inhibitors, emphasizing the need for clear patient counseling regarding black box warnings

Julien Seneschal, MD, PhD: An Update on Topical and Systemic JAK Inhibition for Vitiligo

Dr. Seneschal provides an update on the evolving role of JAK inhibitors in the treatment of Vitiligo, reviewing both currently available topical therapies and investigational

Jennifer Silva, APRN-DNP: Providing Adequate Treatment for Patients with Vitiligo

Jennifer Silva, APRN-DNP, outlines treatment options for patients with vitiligo who have not responded well to traditional therapies. Topics Covered: Challenges in vitiligo treatment Strategies

Iltefat Hamzavi, MD: Combining Phototherapy with Topical Therapy in Patients with Vitiligo

Dr. Hamzavi and James Del Rosso, DO, Editor-in-Chief of Journal of Clinical and Aesthetic Dermatology, discuss practical treatment considerations for patients with Vitiligo using Ruxolitinib>

Gina Mangin, MPAS, PA-C: Coaching Pearls for Patients with Vitiligo

Gina Mangin discusses patient-centered strategies for managing Vitiligo, emphasizing the importance of encouragement, education, and ongoing motivation throughout the treatment journey. Her presentation highlights how

David Rosmarin, MD: Updates in Topical and Systemic Vitiligo Treatment

Dr. Rosmarin reviews key updates in the treatment of Vitiligo, expanding on topics presented during his session at the Masterclasses in Dermatology Meeting. His discussion

Gina Mangin, MPAS, PA-C: Using Light Box Therapy for Patients with Vitiligo

Gina Mangin, MPAS, PA-C, discusses the role of light box therapy in vitiligo management, with a focus on setting clear expectations around treatment timelines and

Shanna Miranti, MPAS, PA-C: Prescribing Ruxolitinib for Patients with Vitiligo

Shanna Miranti, MPAS, PA-C, discusses prescribing considerations for topical ruxolitinib in patients with vitiligo, emphasizing the importance of prior treatment attempts with topical corticosteroids and

Nada Elbuluk, MD: Psychological Comorbidity Assessment and Counseling for Patients with Vitiligo

Nada Elbuluk, MD, discusses the importance of assessing psychological comorbidities in patients with vitiligo by gathering key social information, including daily activities, living situation, and

Shanna Miranti, MPAS, PA-C: Assessing Treatment Efficacy in Patients with Vitiligo

Shanna Miranti, MPAS, PA-C, discusses the similar efficacy seen in patients treated with ruxolitinib at diagnosis versus those who had disease for years.

James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal

Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster

Shanna Miranti, MPAS, PA-C: Managing the Psychosocial Impact of Vitiligo

Shanna Miranti, MPAS, PA-C, discusses the bimodal distribution of vitiligo in male and female individuals and the necessary counseling for those who are managing their

Nada Elbuluk, MD: Connecting Patients with Vitiligo with Supportive Resources

Dr. Elbuluk discusses the importance of connecting patients with vitiligo to supportive resources for preventing and mitigating anxiety and depression related to the condition, especially

Andrea Nguyen, PA-C, MS: Determining Treatment Goals and Expectations for Patients with Vitiligo

Andrea Nguyen discusses how she counsels patients with vitiligo and emphasizes the importance in communicating with patients about consistent application and dosing during a treatment

Nada Elbuluk, MD: New Research on Psychological Comorbidities in Patients with Vitiligo

Dr. Elbuluk discusses a recently published retrospective chart review that she and her colleagues published in the Archives of Dermatological Research, which included all patients

Raj Chovatiya, MD, PhD: Utilizing Ruxolitinib Cream for Patients with Vitiligo

Dr. Chovatiya discusses how to effectively treat patients with nonsegmental vitiligo using topical ruxolitinib cream and the importance in a slow and steady treatment regimen.

Nada Elbuluk, MD, FAAD: Research and Utility of Ruxolitinib Cream for Vitiligo

Dr. Elbuluk discusses results of the clinical trials for ruxolitinib cream in patients with vitiligo and how this treatment is being incorporated into the dermatologist’s

John Harris, MD, PhD: Effective Treatment for Patients with Vitiligo

John Harris, MD, PhD, Chair of Dermatology at UMass Chan Medical School, discusses the impact topical ruxolitinib cream has had on patients with vitiligo. He

Seemal Desai, MD, FAAD: Updated Advancements in Vitiligo Treatment

Seemal Desai, MD, a board-certified dermatologist in private and academic practice in Dallas, Texas, discusses the positive impact a recent topical approval has shown for

Susan Taylor, MD: The Impact of Vitiligo on Patients of Color

Susan Taylor, MD, Professor of Dermatology at The University of Pennsylvania in Philadelphia, Pennsylvania, reviews the burden of vitiligo on patients of color and reviews

Nada Elbuluk, MD: Current and Future Treatment Options for Patients with Vitiligo

Nada Elbuluk, MD, a board certified dermatologist at the University of Southern California in Los Angeles, California, discusses the importance of offering a variety of

John Harris, MD, PhD: The Evolution of Treatments for Vitiligo

John Harris, MD, PhD, Chair of Dermatology at Umass Chan Medical School, reviews the history of treatments for vitiligo, current treatments for vitiligo and their

Pearl Grimes, MD: The Psychological Impact of Vitiligo and Advancements in Treatment

Pearl Grimes, MD, Director of of Vitiligo and Pigmentation Institute of Southern California and Clinical Professor of Dermatology at UCLA discusses exciting advancements in therapy

JCAD Archives